A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

Inclusion Criteria:

1. ≥18 years of age.
2. Subjects with histologically or cytologically confirmed metastatic or unresectableadvanced NSCLC or other solid tumors who have progressed on prior standard therapy,have been intolerant to prior standard therapy, or have refused all other currentlyavailable therapeutic options.
3. Subjects must have evaluable disease according to Response Evaluation Criteria inSolid Tumors (RECIST) v1.1.
4. ECOG PS 0-1.
5. An expected survival time is ≥3 months.
6. Adequate organ function.
7. Subjects in Phase II must agree to provide pre-treatment tumor tissue samples.

Exclusion Criteria:

1. Subjects who have had prior chemotherapy, targeted cancer therapy, immunotherapy, orany investigational anti-cancer treatment within 2 weeks or five half-lives of thetreatment (whichever is longer), prior to the first administration of the study drug.
2. Toxicity (excluding alopecia, peripheral neuropathy, and hypothyroidism) that did notreturn to class 0 or class 1 of NCI CTCAE V5.0 from prior antitumor therapy prior tothe first administration of the study drug.
3. Prior radical radiation therapy completed within 4 weeks prior to the firstadministration of the study drug.
4. Subjects with untreated symptomatic brain metastases.
5. History of interstitial lung disease (ILD).
6. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrentdrainage procedures.
7. Received live virus vaccination within 30 days of first dose of study treatment.